{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:42:48Z","timestamp":1765546968853,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001336","name":"University of the Witwatersrand, Johannesburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Artif. Intell."],"abstract":"<jats:p>The outbreak of coronavirus in the year 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted widespread illness, death, and extended economic devastation worldwide. In response, numerous countries, including Botswana and South Africa, instituted various clinical public health (CPH) strategies to mitigate and control the disease. However, the emergence of variants of concern (VOC), vaccine hesitancy, morbidity, inadequate and inequitable vaccine supply, and ineffective vaccine roll-out strategies caused continuous disruption of essential services. Based on Botswana and South Africa hospitalization and mortality data, we studied the impact of age and gender on disease severity. Comparative analysis was performed between the two countries to establish a vaccination strategy that could complement the existing CPH strategies. To optimize the vaccination roll-out strategy, artificial intelligence was used to identify the population groups in need of insufficient vaccines. We found that COVID-19 was associated with several comorbidities. However, hypertension and diabetes were more severe and common in both countries. The elderly population aged \u226560 years had 70% of major COVID-19 comorbidities; thus, they should be prioritized for vaccination. Moreover, we found that the Botswana and South Africa populations had similar COVID-19 mortality rates. Hence, our findings should be extended to the rest of Southern African countries since the population in this region have similar demographic and disease characteristics.<\/jats:p>","DOI":"10.3389\/frai.2022.1013010","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T08:36:16Z","timestamp":1665650176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Leveraging artificial intelligence to optimize COVID-19 robust spread and vaccination roll-out strategies in Southern Africa"],"prefix":"10.3389","volume":"5","author":[{"given":"Thuso","family":"Mathaha","sequence":"first","affiliation":[]},{"given":"Mhlambululi","family":"Mafu","sequence":"additional","affiliation":[]},{"given":"Onkabetse V.","family":"Mabikwa","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Ndenda","sequence":"additional","affiliation":[]},{"given":"Gregory","family":"Hillhouse","sequence":"additional","affiliation":[]},{"given":"Bruce","family":"Mellado","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00323-6","article-title":"Access to and equitable distribution of COVID-19 vaccine in low-income countries","volume":"6","author":"Acharya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100453","DOI":"10.7554\/eLife.73896","article-title":"Genomic epidemiology of the first two waves of SARS-CoV-2 in Canada","volume":"35","author":"Anderson","year":"2020","journal-title":"Epidemics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/B978-0-323-90769-9.00011-6","article-title":"A review on epidemiology, genomic characteristics, spread, and treatments of COVID-19","author":"Bharati","year":"2022","journal-title":"Data Science for COVID-19"},{"unstructured":"2019","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.3390\/ijerph18157890","article-title":"Leveraging artificial intelligence and big data to optimize COVID-19 clinical public health and vaccination roll-out strategies in Africa","volume":"18","author":"Bruce","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abe6959","article-title":"Model-informed covid-19 vaccine prioritization strategies by age and serostatus","volume":"371","author":"Bubar","year":"2021","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2213-2600(21)00129-6","article-title":"Challenges in the rollout of covid-19 vaccines worldwide","volume":"9","author":"Burki","year":"2021","journal-title":"Lancet Respir. Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162B2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"New Engl. J. Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01736-z","article-title":"Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India","author":"Du","year":"2022","journal-title":"Nat. Med."},{"key":"B13","first-page":"108","article-title":"2019 novel coronavirus","volume":"17","author":"Fagbule","year":"2019","journal-title":"Ann. Ibadan Postgrad. Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1371\/journal.pgph.0000165","article-title":"COVID-19 vaccine brand hesitancy and other challenges to vaccination in the Philippines","volume":"125","author":"Forman","year":"2021","journal-title":"Health Policy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","article-title":"Gender differences in patients with covid-19: focus on severity and mortality","volume":"8","author":"Jin","year":"2020","journal-title":"Front. Publ. Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40779-020-0233-6","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Jin","year":"2020","journal-title":"Milit. Med. Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/14760584.2022.2042257","article-title":"Clinical development and approval of COVID-19 vaccines","volume":"21","author":"Kalinke","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine: a comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat. Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The covid-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"New Engl. J. Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.15212\/ZOONOSES-2022-0001","article-title":"SARS-CoV-2 variants and vaccination","volume":"2","author":"Liu","year":"2022","journal-title":"Zoonoses"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first bnt162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMp2020926","article-title":"Ensuring uptake of vaccines against SARS-CoV-2","volume":"383","author":"Mello","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.semnuclmed.2021.06.004","article-title":"Clinical management of COVID-19 patients-an update","author":"M\u00f8lhave","year":"2022","journal-title":"Seminars in Nuclear Medicine, Vol. 52"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(20)30474-5","article-title":"What could fair allocation of an efficacious COVID-19 vaccine look like in South Africa?","volume":"9","author":"Moodley","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221097248.","article-title":"The race for COVID-19 vaccines: the various types and their strengths and weaknesses","author":"Muhar","year":"2022","journal-title":"J. Pharm. Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.53854\/liim-3001-1","article-title":"A review of adverse effects of COVID-19 vaccines","volume":"30","author":"Mushtaq","year":"2022","journal-title":"Le Infezioni Med"},{"year":"2020","journal-title":"Social Isolation and Loneliness in Older Adults: Opportunities for the Health Care System","key":"B30"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2120.","article-title":"Anaphylaxis and related events post-COVID-19 vaccination: a systematic review","author":"Paul","year":"2022","journal-title":"J. Clin. Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.2020.18513","article-title":"Fairly prioritizing groups for access to COVID-19 vaccines","volume":"324","author":"Persad","year":"2020","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-022-00388-7","article-title":"Oral antiviral treatments for covid-19: opportunities and challenges","author":"Rahmah","year":"2022","journal-title":"Pharmacol. Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/21645515.2020.1827882","article-title":"Who should be prioritised for COVID-19 vaccination?","volume":"17","author":"Russell","year":"2021","journal-title":"Hum. Vaccines Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s42399-020-00363-4","article-title":"Comorbidity and its impact on patients with COVID-19","volume":"2","author":"Sanyaolu","year":"2020","journal-title":"SN Comprehens. Clin. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"100535","DOI":"10.1016\/j.epidem.2021.100535","article-title":"Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland","volume":"38","author":"Shattock","year":"2022","journal-title":"Epidemics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int. J. Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"E497","DOI":"10.1503\/cmaj.200476","article-title":"Mathematical modelling of covid-19 transmission and mitigation strategies in the population of Ontario, Canada","volume":"192","author":"Tuite","year":"2020","journal-title":"CMAJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1164\/rccm.202003-0736LE","article-title":"Clinical course and outcomes of 344 intensive care patients with COVID-19","volume":"201","author":"Wang","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/jama.2021.4300","article-title":"Incentivizing vaccination uptake: the \u201cgreen pass\u201d proposal in Israel","volume":"325","author":"Wilf-Miron","year":"2021","journal-title":"JAMA"},{"year":"2020","journal-title":"Mental Health and Psychosocial Considerations During the COVID-19 Outbreak","key":"B43"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","author":"Wouters","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Artificial Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frai.2022.1013010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T08:36:20Z","timestamp":1665650180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frai.2022.1013010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":44,"alternative-id":["10.3389\/frai.2022.1013010"],"URL":"https:\/\/doi.org\/10.3389\/frai.2022.1013010","relation":{},"ISSN":["2624-8212"],"issn-type":[{"type":"electronic","value":"2624-8212"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"1013010"}}